Synmosa Biopharma Statistics

Total Valuation

Synmosa Biopharma has a market cap or net worth of TWD 16.11 billion. The enterprise value is 18.09 billion.

Market Cap	16.11B
Enterprise Value	18.09B

Important Dates

The next estimated earnings date is Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	Aug 9, 2024

Share Statistics

Synmosa Biopharma has 424.62 million shares outstanding. The number of shares has increased by 7.65% in one year.

Shares Outstanding	424.62M
Shares Change (YoY)	+7.65%
Shares Change (QoQ)	-0.14%
Owned by Insiders (%)	8.82%
Owned by Institutions (%)	5.59%
Float	354.78M

Valuation Ratios

The trailing PE ratio is 23.24 and the forward PE ratio is 17.73.

PE Ratio	23.24
Forward PE	17.73
PS Ratio	3.08
PB Ratio	2.31
P/FCF Ratio	61.59
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.21, with an EV/FCF ratio of 69.14.

EV / Earnings	26.25
EV / Sales	3.49
EV / EBITDA	18.21
EV / EBIT	27.56
EV / FCF	69.14

Financial Position

The company has a current ratio of 2.22, with a Debt / Equity ratio of 30.48.

Current Ratio	2.22
Quick Ratio	1.42
Debt / Equity	30.48
Debt / EBITDA	2.49
Debt / FCF	9.57
Interest Coverage	11.31

Financial Efficiency

Return on equity (ROE) is 6.21% and return on invested capital (ROIC) is 3.83%.

Return on Equity (ROE)	6.21%
Return on Assets (ROA)	3.39%
Return on Capital (ROIC)	3.83%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.42
Inventory Turnover	1.87

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.45% in the last 52 weeks. The beta is 0.27, so Synmosa Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+13.45%
50-Day Moving Average	37.09
200-Day Moving Average	36.03
Relative Strength Index (RSI)	56.44
Average Volume (20 Days)	665,848

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Synmosa Biopharma had revenue of TWD 5.19 billion and earned 689.09 million in profits. Earnings per share was 1.63.

Revenue	5.19B
Gross Profit	2.20B
Operating Income	668.16M
Pretax Income	670.01M
Net Income	689.09M
EBITDA	980.74M
EBIT	668.16M
Earnings Per Share (EPS)	1.63

Full Income Statement

Balance Sheet

The company has 1.83 billion in cash and 2.50 billion in debt, giving a net cash position of -673.58 million or -1.59 per share.

Cash & Cash Equivalents	1.83B
Total Debt	2.50B
Net Cash	-673.58M
Net Cash Per Share	-1.59
Equity (Book Value)	8.22B
Book Value Per Share	16.46
Working Capital	2.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 531.15 million and capital expenditures -269.52 million, giving a free cash flow of 261.63 million.

Operating Cash Flow	531.15M
Capital Expenditures	-269.52M
Free Cash Flow	261.63M
FCF Per Share	0.62

Full Cash Flow Statement

Margins

Gross margin is 42.48%, with operating and profit margins of 12.88% and 13.29%.

Gross Margin	42.48%
Operating Margin	12.88%
Pretax Margin	12.92%
Profit Margin	13.29%
EBITDA Margin	18.91%
EBIT Margin	12.88%
FCF Margin	5.05%

Dividends & Yields

This stock pays an annual dividend of 0.55, which amounts to a dividend yield of 1.45%.

Dividend Per Share	0.55
Dividend Yield	1.45%
Dividend Growth (YoY)	18.41%
Years of Dividend Growth	3
Payout Ratio	28.22%
Buyback Yield	-7.65%
Shareholder Yield	-6.20%
Earnings Yield	4.30%
FCF Yield	1.62%

Dividend Details

Stock Splits

The last stock split was on August 9, 2024. It was a forward split with a ratio of 1.1.

Last Split Date	Aug 9, 2024
Split Type	Forward
Split Ratio	1.1